Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | LPL | P06858 | 3/20 | 0.35 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | JAK2 | O60674 | 2/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA4 | P22748 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | AMY1A | P0DUB6 | 2/20 | 0.33 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29960842 | 1.00 | EGFR (0.45) | EGFRCYP19A1LPLLIPGALDH1A1 | |
| SCHEMBL23083617 | 0.85 | EGFR (0.38) | EGFRLPLLIPGALDH1A1CA1 | |
| SCHEMBL24773231 | 0.84 | LPL (0.42) | EGFRLPLLIPGJAK2BTK | |
| SCHEMBL28147238 | 0.83 | EGFR (0.39) | EGFRLPLLIPGALDH1A1CA12 | |
| SCHEMBL26111348 | 0.83 | ALDH1A1 (0.39) | EGFRLPLLIPGALDH1A1JAK2 | |
| SCHEMBL21752122 | 0.83 | EGFR (0.35) | EGFRLPLLIPGJAK2BTK | |
| SCHEMBL2774133 | 0.82 | CA1 (0.44) | EGFRLPLLIPGALDH1A1CA12 | |
| SCHEMBL30237979 | 0.82 | CA1 (0.44) | EGFRLPLLIPGALDH1A1CA12 | |
| SCHEMBL1870652 | 0.81 | JAK2 (0.38) | EGFRLPLLIPGALDH1A1JAK2 | |
| SCHEMBL21751373 | 0.80 | EGFR (0.36) | EGFRLPLLIPGJAK2BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12459951-B2 | Compounds that interact with RAS superfamily proteins for treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | SHY THERAPEUTICS, LLC (US) | 2025-11-04 | — | — | US | disclosed |
| US-12234218-B2 | Heterocyclic compounds as modulators of mGluR7 | PRAGMA THERAPEUTICS (FR) | 2025-02-25 | — | — | US | disclosed |
| US-20240360141-A1 | COMPOUNDS THAT INTERACT WITH RAS SUPERFAMILY PROTEINS FOR TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | SHY THERAPEUTICS, LLC | 2024-10-31 | — | — | US | disclosed |
| WO-2024175081-A1 | SHP2 INHIBITOR COMPOUND AND USE THEREOF | 深圳真实生物医药科技有限公司 | 2024-08-29 | — | — | WO | disclosed |
| US-20220363664-A1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF MGLUR7 | PRAGMA THERAPEUTICS (FR) | 2022-11-17 | — | — | US | disclosed |
| US-11459305-B2 | Processes for the preparation of uracil derivatives | NEUROCRINE BIOSCIENCES, INC. (US) | 2022-10-04 | — | — | US | disclosed |
| US-11414395-B2 | Heterocyclic compounds as modulators of mGluR7 | PRAGMA THERAPEUTICS (FR) | 2022-08-16 | — | — | US | disclosed |
| US-20200255387-A1 | PROCESSES FOR THE PREPARATION OF URACIL DERIVATIVES | NEUROCRINE BIOSCIENCES, INC. | 2020-08-13 | — | — | US | disclosed |
| US-20200255387-A1 | PROCESSES FOR THE PREPARATION OF URACIL DERIVATIVES | NEUROCRINE BIOSCIENCES, INC. | 2020-08-13 | — | — | US | disclosed |
| US-20200231563-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS MODULATORS OF MGLUR7 | PRAGMA THERAPEUTICS (FR) | 2020-07-23 | — | — | US | disclosed |
| US-9376436-B2 | 2-(pyridin-2yl)-1, 7-diaza-spiro [4.4] nonane-6-one compound as voltage-gated sodium channels modulators | Convergence Pharmaceuticals Limited (GB) | 2016-06-28 | — | — | US | disclosed |
| EP-2794612-B1 | 2-(PYRIDIN-2YL)-1,7-DIAZA-SPIRO[4.4]NONANE-6-ONE COMPOUNDS AS VOLTAGE-GATED SODIUM CHANNELS MODULATORS | CONVERGENCE PHARMACEUTICALS (GB) | 2016-04-06 | — | — | EP | disclosed |
| US-20150225400-A1 | 2 - (PYRIDIN- 2YL)- 1, 7 -DIAZA-SPIRO [4.4] NONANE- 6 -ONE COMPOUND AS VOLTAGE-GATED SODIUM CHANNELS MODULATORS | Convergence Pharmaceuticals Limited (GB) | 2015-08-13 | — | — | US | disclosed |
| US-8765948-B2 | Processes for the preparation of uracil derivatives | NEUROCRINE BIOSCIENCES, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765948-B2 | Processes for the preparation of uracil derivatives | NEUROCRINE BIOSCIENCES, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765948-B2 | Processes for the preparation of uracil derivatives | NEUROCRINE BIOSCIENCES, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20110098472-A1 | PROCESSES FOR THE PREPARATION OF URACIL DERIVATIVES | NEUROCRINE BIOSCIENCES, INC. | 2011-04-28 | — | — | US | disclosed |
| US-20110098472-A1 | PROCESSES FOR THE PREPARATION OF URACIL DERIVATIVES | NEUROCRINE BIOSCIENCES, INC. | 2011-04-28 | — | — | US | disclosed |
| WO-2009062087-A1 | PROCESSES FOR THE PREPARATION OF URACIL DERIVATIVES | NEUROCRINE BIOSCIENCES, INC. (US) | 2009-05-14 | — | — | WO | disclosed |
| WO-2009062087-A1 | PROCESSES FOR THE PREPARATION OF URACIL DERIVATIVES | NEUROCRINE BIOSCIENCES, INC. (US) | 2009-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200255387-A1 | PROCESSES FOR THE PREPARATION OF URACIL DERIVATIVES | GNRHR, FSHR, GHRHR | EGFR 2041/4885CYP19A1 54/4885LPL 3741/4885 |
| US-20200231563-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS MODULATORS OF MGLUR7 | GRM7, GRM1, GRM3 | EGFR 1485/4885CYP19A1 4467/4885LPL 3834/4885 |
| US-12234218-B2 | Heterocyclic compounds as modulators of mGluR7 | GRM7, GRM1, GRM2 | EGFR 1531/4885CYP19A1 4219/4885LPL 2749/4885 |
| US-20150225400-A1 | 2 - (PYRIDIN- 2YL)- 1, 7 -DIAZA-SPIRO [4.4] NONANE- 6 -ONE COMPOUND AS VOLTAGE-GATED SODIUM CHANNELS MODULATORS | SCN1A, SCN2A, SCN1B | EGFR 4547/4885CYP19A1 3554/4885LPL 3512/4885 |
| US-20220363664-A1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF MGLUR7 | GRM7, GRM1, GRM2 | EGFR 1531/4885CYP19A1 4219/4885LPL 2749/4885 |
| US-12459951-B2 | Compounds that interact with RAS superfamily proteins for treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | KRAS, HRAS, NRAS | EGFR 591/4885CYP19A1 3830/4885LPL 3118/4885 |
| US-20110098472-A1 | PROCESSES FOR THE PREPARATION OF URACIL DERIVATIVES | GNRHR, FSHR, GHRHR | EGFR 2041/4885CYP19A1 54/4885LPL 3741/4885 |
| US-20240360141-A1 | COMPOUNDS THAT INTERACT WITH RAS SUPERFAMILY PROTEINS FOR TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | KRAS, HRAS, NRAS | EGFR 591/4885CYP19A1 3830/4885LPL 3118/4885 |
| US-11414395-B2 | Heterocyclic compounds as modulators of mGluR7 | GRM7, GRM1, GRM3 | EGFR 1411/4885CYP19A1 4284/4885LPL 3669/4885 |
| US-11459305-B2 | Processes for the preparation of uracil derivatives | GNRHR, FSHR, GHRHR | EGFR 2041/4885CYP19A1 54/4885LPL 3741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.